Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis - 21/04/16
Amy Paller, MS, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Wynnis Tom, MD, University of California, San Diego and Rady Children’s Hospital, San Diego, CA, United States; Mark M. Lebwohl, MD, Mount Sinai Health System, New York, NY, United States; Robin L. Blumenthal, PhD, Anacor Pharmaceuticals, Palo Alto, CA, United States; Mark Boguniewicz, MD, National Jewish Health, Denver, CO, United States; Lawrence S. Eichenfield, MD, University of California, San Diego, San Diego, CA, United States; Douglass W. Forsha, MD, South Valley Dermatology, West Jordan, UT, United States; Eric L. Simpson, MD, Oregon Health and Science University, Portland, OR, United States; Linda Stein Gold, MD, Henry Ford Hospital, Detroit, MI, United States; Andrea L. Zaenglein, MD, Pennsylvania State University and Milton S. Hershey Medical Center, Hershey, PA, United States; R. S. Call, Clinical Research Partners, Richmond, VA, United States; W. C. Rees, PI-Coor Clinical Research, Burke, VA, United States; L. T. Zane, Anacor Pharmaceuticals, Inc, Palo Alto, CA, United States; A. A. Hebert, University of Texas Health Science Center Houston, Houston, TX, United States
Le texte complet de cet article est disponible en PDF. Anacor Pharmaceuticals has provided editorial and printing support. |
Vol 74 - N° 5S1
P. AB86 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?